Pharmacokinetics Study of Mycophenolic Acid in Early Renal Transplant Patients
LUO Yong-ganga, ZHU Zhen-fengb, SUN Zhib, LI Zhuo-lunb, SHI Ying-yingb, LIU Li-weib, ZHANG Junb*, ZHANG Xiao-jianb*
The First Affiliated Hospital of Zhengzhou University, a. Department of Integrated Intensive Care Unit; b. Department of Pharmacy, Zhengzhou 450052, China
Abstract��OBJECTIVE To investigate the pharmacokinetic characteristics of enteric-coated sodium mycophenolate(EC-MPS) or mycophenolate mofetil (MMF) dispersible tablets after multiple oral doses in early renal transplant patients, providing references for the rational use of the study drugs in clinical practice. METHODS Thirty-eight first-time renal transplant patients were selected and randomly divided into EC-MPS group (n=18) or MMF dispersible tablets group (n=19). The patients received EC-MPS (540 mg, q12h) or MMF dispersible tablets (750 mg, q12h), combined with tacrolimus and methylprednisolone to prevent acute rejection, respectively. Blood samples were collected at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 h after oral administration on the postoperative day 5. Enzyme multiplied immunoassay technique (EMIT) was employed to determine the plasma concentration of MPA. The main pharmacokinetic parameters of the two durgs were assessed. RESULTS Pharmacokinetic parameters on the postoperative day 5 of EC-MPS and MMF dispersible tablet were as follows: AUC0-12 h were(43.62��16.20) and(42.02��14.40)mg��h��L-1(P>0.05);��max were (17.85��11.32) and (13.96��5.11) mg��L-1(P>0.05);tmax were (2.72��1.74) and(1.32��0.42)h(P<0.05); ��0 were (1.63��1.18) and (1.66��0.93) mg��L-1(P>0.05); ��12 were(1.84��2.09) and (1.81��1.76) mg��L-1(P>0.05); CL were (14.12��5.30) and (19.66��5.99) L��h-1(P<0.05). Most of the patients revealed a second small peak in the 4-12 h after taking MPA in the two study groups. CONCLUSION There are large individual differences of pharmacokinetic between EC-MPS and MMF dispersible tablets in early renal transplant patients. It is necessary to carry out therapeutic drug monitoring of MPA to guide the adjustment of drug dosage.
������, �����, ��־, ����, ʦӨӨ, ����ΰ, �ſ�, ������. ��������������ֲ�����е�ҩ��ѧ�о�[J]. �й�ҩѧ��־, 2018, 53(18): 1589-1593.
LUO Yong-gang, ZHU Zhen-feng, SUN Zhi, LI Zhuo-lun, SHI Ying-ying, LIU Li-wei, ZHANG Jun, ZHANG Xiao-jian. Pharmacokinetics Study of Mycophenolic Acid in Early Renal Transplant Patients. Chinese Pharmaceutical Journal, 2018, 53(18): 1589-1593.
PELLETIER R P, AKIN B, HENRY M L, et al. The impact of mycophenolate mofetil dosing patterns on outcomes in renal transplantation . Clin Transplant,2003, 17(3):200-205.
[2]
SÁNCHEZ FRUCTUOSO A,CALVO N,MORENO M A,et al. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil . Transplant Proc, 2007, 39(7): 2194-2196.
[3]
VAN GELDER T, HILBRANDS L B, VANRENTERGHEM Y, et al. A randomized double-blind,multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation . Transplantation, 1999, 68(2):261-266.
[4]
WEBER L T, SHIPKOVA M, ARMSTRONG V W, et al. Comparison of the emit immunoassay with hplc for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. Clin Chem, 2002, 48(3):517-525.
[5]
YAO X L, HUANG H, WEI C, et al. Limited sampling strategy for mycophenolic acid in Chinese kidney transplant recipients receiving enteric-coated mycophenolate sodium and tacrolimus during the early posttransplantation phase. Ther Drug Monit, 2015, 37(4):516-523.
[6]
ZHANG J, JIA M M, ZUO L H, et al. Nonlinear relationship between enteric-coated mycophenolate sodium dose and mycophenolic acid exposure in Han kidney transplantation recipients. Acta Pharm Sin B(ҩѧѧ��Ӣ�İ�), 2017, 7(3):347-352.
[7]
DE WINTER B C, MATHOT R A, SOMBOGAARD F, et al. Nonlinear relationship between mycophenolatemofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. Clin J Am Soc Nephrol, 2011, 6(3):656-663.
[8]
STAATZ C E,TETT S E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients . Clin Pharmacol, 2007, 46(1):13-58.
YU Z C, ZHOU P J, WANG X H, et al. Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients. Acta Pharmacol Sin(�й�ҩ��ѧ��), 2017, 38(11): 1566-1579.
[11]
JEONG H, KAPLAN B. Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol,2007, 2(1): 184-191.
[12]
ARNS W,CIBRIK D M,WALKER R G,et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: review of the literature. Transplant,2006, 82(8):1004-1012.
[13]
ZHANG J, JIA M M, ZUO L H, et al. Pharmacokinetics study of mycophenolate mofetil dispersible tablets in early renal transplant patients. Chin Pharm J(�й�ҩѧ��־),2017, 52(8):666-670.
2018, Vol. 53 
